A 38-year-old woman on levothyroxine 75 mcg daily for Hashimoto's thyroiditis presents for follow-up. She reports persistent fatigue and weight gain despite compliance. TSH is 0.2 mIU/L (normal 0.5–5.0) and free T4 is 1.9 ng/dL (normal 0.8–1.8). What is the most appropriate next step?

Explanation

## Clinical Scenario Analysis This patient has **biochemical over-replacement**: TSH is suppressed at 0.2 mIU/L (below the lower limit of 0.5) and free T4 is elevated at 1.9 ng/dL (above the upper limit of 1.8 ng/dL). Despite reporting fatigue and weight gain — symptoms more consistent with hypothyroidism — the laboratory findings clearly indicate **iatrogenic hyperthyroidism (over-treatment)**. The most appropriate next step is to **reduce the levothyroxine dose**. ## Biochemical Interpretation | Parameter | Patient Value | Normal Range | Interpretation | |-----------|---------------|--------------|----------------| | **TSH** | 0.2 mIU/L | 0.5–5.0 | Suppressed — over-replacement | | **Free T4** | 1.9 ng/dL | 0.8–1.8 | Above upper limit — elevated | | **Clinical status** | Fatigue, weight gain | — | Atypical for hyperthyroidism; may reflect early/subclinical over-replacement or co-existing issues | **Key Point:** When TSH is suppressed AND free T4 is above the reference range, the primary intervention is **dose reduction**. Investigating alternative causes (Option B) before correcting the over-replacement is inappropriate — the biochemical abnormality must be addressed first, as it is the most likely contributor and carries significant long-term risks. ## Why Reduce the Dose? Per **Harrison's Principles of Internal Medicine (21st ed.)** and **ATA 2014 guidelines**, the goal of levothyroxine replacement in Hashimoto's thyroiditis is to maintain TSH within the normal reference range (0.5–5.0 mIU/L). A suppressed TSH with elevated free T4 indicates excess hormone delivery and mandates dose reduction. Reducing from 75 mcg to 50 mcg daily is appropriate, with TSH and free T4 rechecked in 6–8 weeks. **Clinical Pearl:** Chronic over-replacement with levothyroxine carries significant risks: - **Atrial fibrillation** (2–3× increased risk with suppressed TSH) - **Accelerated bone loss and osteoporosis** (especially in post-menopausal women) - **Myocardial ischemia** in susceptible individuals - **Worsening anxiety, palpitations, and insomnia** ## Why Not the Other Options? - **Option B (Maintain dose, investigate alternatives):** Incorrect as the primary step. While alternative causes of fatigue may eventually be explored, the biochemical over-replacement must be corrected first. Maintaining an over-replacing dose exposes the patient to unnecessary cardiovascular and skeletal risks. - **Option D (Increase to 100 mcg):** Contraindicated. This would worsen over-replacement and increase risk of serious adverse effects. - **Option A (Switch to desiccated thyroid extract):** Not indicated. There is no evidence of inadequate T3 conversion, and switching formulations does not address the over-replacement. ## Management Algorithm ``` TSH suppressed + Free T4 elevated ↓ Reduce levothyroxine dose (75 mcg → 50 mcg) ↓ Recheck TSH + Free T4 in 6–8 weeks ↓ If symptoms persist despite normalized TSH → Investigate alternative causes ``` **High-Yield:** In NEET PG/INI-CET scenarios, when TSH is below normal AND free T4 is above normal in a patient on levothyroxine, the answer is always **dose reduction** — not investigation of alternative causes as the first step. **Mnemonic:** **STOP-T4** — **S**uppressed TSH + **T**oo-high free T4 → **O**ver-replacement → **P**rescribe lower dose → **T**itrate to normal **4** (T4) and TSH.